Behaviour science: the new capability every pharma ..

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-09-13T11:25:33.737Z • Permanent link

Recent developments in the field of behaviour science have sent shockwaves through the pharmaceutical industry, highlighting a previously overlooked yet highly valuable capability that could revolutionize the way companies approach product development and marketing. This new capability, known as "behavioural insights," has been gaining traction among pharma companies, research institutions, and policymakers, with significant implications for the industry as a whole.

At the forefront of this shift is Dr. Wendy Wood, a renowned behavioural scientist at the University of Southern California, who has been pioneering the use of behaviour science in pharmaceutical product development. Her work has focused on understanding how people's attitudes and beliefs influence their health behaviours, and how this knowledge can be used to design more effective interventions. Wood's research has been widely cited and has influenced the development of several pharmaceutical products, including a new treatment for smoking cessation.

Meanwhile, companies such as Pfizer and GlaxoSmithKline have been investing heavily in behaviour science research, recognizing the potential for this capability to improve product outcomes and customer engagement. For example, Pfizer's " Behavioural Insights for Better Health" initiative aims to use behaviour science to improve patient engagement and adherence to treatment plans. Similar initiatives are underway at GlaxoSmithKline, where researchers are exploring the use of behavioural insights to design more effective patient education programs.

The impact of behaviour science on the pharmaceutical industry will be felt far beyond the company walls, with significant implications for patients, policymakers, and the broader healthcare system. One of the most significant consequences will be improved patient outcomes, as behaviour science can help design more effective interventions that take into account the complex psychological and social factors that influence health behaviours. For example, a recent study published in the Journal of the American Medical Association found that a behaviourally informed medication adherence program resulted in significant improvements in patient outcomes, compared to traditional approaches.

Pharmaceutical companies that fail to adapt to this new capability risk falling behind their competitors, while also missing out on opportunities to improve patient outcomes and reduce healthcare costs. Research communities and policymakers will also need to take notice, as behaviour science has the potential to inform more effective policy interventions and healthcare system design. Companies such as Novartis and Merck have already begun to explore the use of behaviour science in their product development pipelines, recognizing the potential for this capability to drive innovation and improve patient outcomes.

Behaviour science has been gaining traction in the pharmaceutical industry in recent years, but it is not a new phenomenon. In fact, the field of behaviour science has its roots in the 19th-century work of Gustave Le Bon, who wrote extensively on the role of psychology in shaping human behaviour. More recently, the work of behavioural economists such as Richard Thaler and Cass Sunstein has helped to establish the field as a major area of research. However, the current shift towards behaviour science in the pharmaceutical industry is driven by advances in data analytics and machine learning, which have enabled researchers to tap into vast amounts of behavioural data and apply sophisticated analytical techniques to gain insights into human behaviour.